Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT03636880 Recruiting - Depression Clinical Trials

Heart Failure Insomnia Treatment Study

Start date: February 24, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to compare a short, behavioral treatment for insomnia with sleep monitoring to determine whether these approaches are effective in reducing insomnia and improving sleep quality among patients with heart failure (HF). This study will also examine the relationship between insomnia and cognitive functioning in HF and the effects of the behavioral treatment on cognitive functioning, self-care, distress, HF symptoms, and functional status. Participants will be randomly assigned to four-sessions of a behavioral treatment (Brief Behavioral Treatment for Insomnia; BBTI) or sleep monitoring.

NCT ID: NCT03634969 Not yet recruiting - Cardiac Failure Clinical Trials

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Start date: August 15, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.

NCT ID: NCT03634189 Not yet recruiting - Heart Failure Clinical Trials

Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C

Start date: March 1, 2019
Phase: Phase 1
Study type: Interventional

Cannabidiol in heart failure

NCT ID: NCT03631654 Not yet recruiting - Clinical trials for Heart Failure NYHA Class IV

Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

Ivabradine, a selective inhibitor of the If current in the sinoatrial node, provides heart rate reduction and leads to a reduction in heart failure hospitalizations. For this reason, the American College of Cardiology (ACC) and the American Heart Association (AHA) guidelines provide a class IIa recommendation for ivabradine in stable heart failure patients with LVEF 35% and New York Heart Association (NYHA) class II-III symptoms who are on a beta blocker at maximum tolerated dose with a resting heart rate of 70 beats per minute or greater. While ivabradine leads to improvement in outcomes in stable NYHA class II-III chronic heart failure patients, its role in class IV, stage D heart failure, and cardiogenic shock is less clear. Ivabradine's effect on acute cardiogenic shock has been evaluated by two recent studies. In the MODIFY trial, a randomized control study evaluating ivabradine in patients with multiorgan dysfunction, the addition of ivabradine did not result in significant heart rate reductions or other positive clinical outcomes. However, a small prospective trial demonstrated a significant decrease in heart rate and NT-proBNP with the addition of ivabradine in patients with acute cardiogenic shock on dobutamine. While few data investigate ivabradine's role in acute cardiogenic shock, it has yet to be studied in heart failure patients on long-term inotropic therapy. Inotropes such as dobutamine and milrinone result in tachycardia and may lead to ventricular arrhythmias. Moreover, patients on chronic inotropes are typically off beta blockers and have few pharmacological options available to help reduce heart rates. Ivabradine may have a role in decreasing heart rate and improving outcomes in patients on chronic inotropes. Given the benefits of ivabradine in stable chronic heart failure patients, we plan to perform a study investigating the role of ivabradine in NYHA Stage D patients on home inotropes. Our primary objective is to analyze changes in two cardiac biomarkers, NT-proBNP and high-sensitivity troponin. Our secondary outcomes include changes in noninvasive echocardiographic hemodynamics, changes in arrhythmia burden, and heart failure symptom modification based on 6-minute walk test results.

NCT ID: NCT03629340 Not yet recruiting - Heart Failure Clinical Trials

Metformin for PH+HFpEF

Start date: September 2018
Phase: Phase 2
Study type: Interventional

The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.

NCT ID: NCT03628443 Recruiting - Heart Failure Clinical Trials

Cardiorenal Risk Stratification Pilot Study

Start date: July 19, 2018
Study type: Observational

This is prospective cohort study with the purpose of improving our understanding of morbidity and mortality risk in patients with heart failure and chronic kidney disease.

NCT ID: NCT03627585 Not yet recruiting - Clinical trials for Heart Failure, Systolic

Reprogramming to Prevent Progressive Pacemaker-induced Remodelling

Start date: August 2018
Phase: N/A
Study type: Interventional

The aim is to provide evidence of the long-term benefits of personalised pacemaker programming on heart function and battery longevity. This will be achieved by showing in a single centre, phase II, double-blind, randomised, placebo-controlled trial that reducing the amount of pacemaker beats to a minimum reverses these changes and extends battery life.

NCT ID: NCT03624010 Not yet recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Start date: October 2018
Phase: Phase 2
Study type: Interventional

PH-HFpEF patients will receive weekly open-label doses of levosimendan and be periodically evaluated for safety and effectiveness in extended use.

NCT ID: NCT03623165 Recruiting - Clinical trials for Heart Failure NYHA Class III

PRODIGY Registry in NYHA Class III Heart Failure Patients

Start date: August 1, 2018
Study type: Observational [Patient Registry]

This is an observational, prospective, single arm, multi-center registry to evaluate the Cordellaâ„¢ Heart Failure System (CHFS) in up to 250 NYHA Class III HF patients .

NCT ID: NCT03621618 Not yet recruiting - Sepsis Clinical Trials

Clinical Assessment of Arterial Dynamic Elastance in ICU Patients, Dependent on Inotropic or Vasopressor Drugs.

Start date: August 15, 2018
Phase: N/A
Study type: Interventional

The primary goal of the study is to determine Eadyn ( = PPV/SVV) as a functional measure of arterial load, in conjunction with other actual afterload indices, systemic vascular resistance and arterial elastance. A secondary aim is the assessment of the influences of vasopressors and inotropic drugs on Eadyn, as a parameter of ventriculo-arterial coupling.